Summary
Merck & Co., Inc. (MRK) announced the completion of the separation of its Organon & Co. business segment, which housed its women's health, biosimilars, and established brands divisions. This separation occurred on June 2, 2021, following a distribution of Organon common stock to Merck shareholders of record as of May 17, 2021. Each Merck shareholder received one-tenth of a share of Organon for every share of Merck they held, with cash provided for fractional shares. The company structured this distribution to be tax-free for its shareholders, with the exception of cash received for fractional shares, making this a significant strategic move for Merck to focus on its core growth areas.
Key Highlights
- 1Merck completed the separation of its Organon & Co. business segment on June 2, 2021.
- 2Organon encompasses Merck's former women's health, biosimilars, and established brands businesses.
- 3A pro rata distribution of Organon common stock was made to Merck shareholders of record on May 17, 2021.
- 4Shareholders received one-tenth of an Organon share for each Merck share held.
- 5Cash will be provided in lieu of fractional Organon shares.
- 6The distribution is designed to be tax-free for Merck shareholders, excluding cash for fractional shares.